Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Philadelphia, Pennsylvania 19107


The purpose of this study it to determine whether supplemental treatment with Iscar improves immune function and quality of life among Stage IV non-small cell lung carcinoma patients receiving conventional chemotherapy. Iscar is an herbal medicine made from the total plant extract of mistletoe. this preparation is already in use in Europe and its use in the US is likely to increase as cancer patients continue to seek alternative therapies.

Study summary:

See Brief Summary


Inclusion Criteria: - Stage IV NSCLC patients who receive standard chemotherapy Exclusion criteria: - Known allergy to Viscum Album L. - Concomitant use of other mistletoe products - Concomitant use of mushroom glucan and proteoglycan extracts - Concomitant use of thymus extract products - Inability to self-report quality of life utilizing assessment tools - Ongoing steroid or ACTH therapy - Co-morbid immunocompromised state - Pregnancy - Participation in other clinical trials



Primary Contact:

Principal Investigator
Steven Rosenzweig, MD
Jefferson Medical College of Thomas Jefferson University

Backup Contact:


Location Contact:

Philadelphia, Pennsylvania 19107
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.